Detecting diabetic eye disease early helps prevent vision loss

Innovative screening programs are reducing the leading cause of blindness in Wisconsin working-age adults
June 9, 2025
Share

Jeri Shultis knew something was wrong. He had driven south from Mauston, Wisconsin to Madison to watch his grandson wrestle at the state tournament, but he was struggling to focus on the mat.

“My eyes were just so blurry all day,” Shultis recalled. “I made an appointment soon after, and the optometrist asked me if I had ever been diagnosed with diabetes.”

Shultis never had, but follow-up testing revealed that he did indeed have the disease. In 2016, he started diabetes treatment at Mile Bluff Medical Center, a UW Health affiliate, in Mauston. Part of that treatment included regular screenings to monitor his eye health.

Approximately 423,000 people in Wisconsin have been diagnosed with diabetes (9.1% of the adult population). Like Shultis, an additional 135,000 people in the state have diabetes but don’t know it, which puts them at risk for complications. Diabetes can cause eye disease, particularly a condition called diabetic retinopathy. High blood sugar damages the tiny blood vessels in the retina, which can cause scarring and ultimately, retinal detachment and blindness. Diabetic retinopathy is the leading cause of blindness among working-age adults in Wisconsin, but early diagnosis and treatment decrease the risk of vision loss by 90%. Currently, fewer than 70,000 Wisconsinites with diabetes receive yearly eye screening.

Researchers in the University of Wisconsin School of Medicine and Public Health’s Department of Ophthalmology and Visual Sciences are working to change that. Dr. Yao Liu, an associate professor of ophthalmology, started a screening program at the Mile Bluff Medical Center soon after she began traveling from Madison to Mauston each month to treat patients.

“Juneau County, which includes Mauston, is an area of great need,” she said. “I saw many patients there with very advanced eye disease who, had they had access to treatment much earlier, would have had better outcomes.”

Dr. Yao Liu points to a retinal scan on a computer monitor
Yao Liu views a retinal eye photo.

Working with Mile Bluff’s chief medical officer Dr. Timothy Bjelland, Liu helped primary care clinics learn to use a retinal camera to take photos of patients’ eyes during routine diabetes checkups. The clinics then send the images to specialists at UW Health, who review and recommend follow-up care for patients who show signs of diabetic retinopathy. This type of screening service, known as teleophthalmology, is critical for patients with less access to eye care specialists.

Beginning in 2015, Liu has conducted research to track the program’s impact over time and identify the barriers and opportunities presented by teleophthalmology. She developed a coaching program called I-SITE to help primary care clinics better integrate this screening technology into their daily work. She also set up a Diabetes Patient Advisory Council in Mauston to engage with patients and gather their input on effective ways to educate and inform the community.

Jeri Shultis joined Liu’s patient advisory council in 2017. He had been proactive in managing his diabetes since his diagnosis, and wanted to help get the word out about the screenings.

Shultis described how the advisory committee arranged for the retinal camera to be on-site to provide free demonstrations at Mauston’s monthly Sharing Supper, a community dining experience intended to build relationships “free of social or economic barriers.”

“Our committee helped explain to community members how the camera worked. It’s not hard at all, and you don’t have to have your eyes dilated,” he recalled.

To date, more than 2,000 patients have received vision-saving eye care as a result of the screening program at Mile Bluff Medical Center. Screening rates, below the national average when the program started, increased substantially to the top quartile nationally.

“Feedback has been very positive,” said Liu. “Primary care clinicians and patients have appreciated it, because it is often difficult to get people in to see an eye doctor. Getting screened the same day you are already in the primary care clinic is helpful to everyone.”

In 2021, with funding from the National Eye Institute, Liu launched a clinical trial at 12 other rural clinics around the country, to determine whether the success at Mile Bluff Medical Center could be replicated elsewhere. In addition to Fort HealthCare and Reedsburg Area Medical Center in Wisconsin, her team works with health systems in Alabama, California, Colorado, New York, Ohio, Tennessee and Vermont. What works for one clinic may not work for others, and Liu’s team wants to understand as much as possible about the barriers, as well as the opportunities for success.

Ultimately, Liu would like to see teleophthalmology become standard at every primary care clinic in the country. She would also like to see Wisconsin leading the nation with the highest screening rates for diabetic eye disease and the lowest rates of diabetes-related blindness. The goal builds on a UW legacy:  The international guidelines for treating diabetic eye disease were developed at UW–Madison, thanks to a 1970s study led by Dr. Matthew “Dinny” Davis.

“We have known for 50 years that we can treat this disease, and it’s still the leading cause of blindness in this country,” Liu said. “That’s mostly due to lack of screening.”

Roomasa Channa

Addressing that lack means testing new ways of making screening more efficient and effective. Approximately twenty to thirty percent of diabetes patients screened for eye disease require referral to a specialist who may perform interventions such as injections in the eye, laser treatments or surgery. For these patients, time is of the essence. Dr. Roomasa Channa, an associate professor of ophthalmology, studies a screening method that relies on artificial intelligence (AI) to provide immediate results. Unlike standard teleophthalmology, where a primary care clinic sends images to eye specialists elsewhere, an AI-based teleophthalmology program reads the image as soon as it’s taken.

“Because the tool can recognize the distinctive hallmarks of diabetic retinopathy, the clinician can tell the patient right away whether or not they have referrable disease,” Channa said.

This increases the likelihood, she said, that patients will follow up with recommended eye care. In medically underserved areas, once patients leave the office, clinicians can lose contact with them for extended periods. Channa’s lab developed a strategy called AI-BRIDGE that incorporates culturally adapted patient education and helps local clinics schedule appropriate follow-up eye appointments for patients. In August 2024, she was approved for a national clinical trial funded by the National Institutes of Health (NIH) and the National Eye Institute to test the effectiveness of AI-BRIDGE at nine clinics around the country.

Last month, the NIH purported to terminate the funding opportunity for the award. Wisconsin is a plaintiff in a multi-state lawsuit aimed at reinstating terminated NIH grants, and the fate of the funding for Channa’s grant is uncertain at the time of this story’s publication.

“Wherever diabetes is increasing, so is diabetic retinopathy,” said Channa. “This broadly impacts people living in medically underserved communities. As one example, here in Wisconsin, our Native and Hispanic populations are more likely to have limited access to health care and have growing rates of diabetes. This leaves them particularly vulnerable to severe complications like blindness.”

A retinal eye photo of a patient with diabetic retinopathy. In the image on the right, diabetic retinopathy lesions are outlined by an AI algorithm.

Channa said that both standard teleophthalmology and AI-based programs offer busy clinicians options based on what works best for them, their clinics and their patients.

Liu and Channa collaborate on research to promote improved vision outcomes and share the goal of helping patients recognize the importance of screenings and treatment.

“People living in medically underserved communities need a voice,” said Channa. “Everyone deserves access to the best medical expertise our country has to offer. This research is aimed at providing efficient, effective diabetic retinopathy screening to communities that currently have the worst outcomes. Our goal is to use innovative systems to save sight.”


Research at the University of Wisconsin–Madison drives innovation, saves lives, creates jobs, supports small businesses, and fuels the industries that keep America competitive and secure. It makes the U.S. — and Wisconsin — stronger. Federal funding for research is a high-return investment that’s worth fighting for. Learn more about the impact of UW–Madison’s federally funded research and how you can help.


Dr. Liu’s research was supported by National Institutes of Health/National Eye Institute Grants UG1EY032446 and K23EY026518, a New Investigator Award from the Wisconsin Partnership Program, a Baldwin Wisconsin Idea Endowment Award from the University of Wisconsin–Madison, an Evidence 2 Implementation Award ULTR002373 from the UW–Madison Institute for Clinical and Translational Research under National Institutes of Health/National Center for Advancing Translational Sciences, and a grant to the Department of Ophthalmology and Visual Sciences, UW School of Medicine and Public Health from Research to Prevent Blindness, Inc.

Dr. Channa’s work was supported by National Institutes of Health/National Eye Institute Grants K23EY030911 and 1R01EY035994, and by a Vilas Research Award.